Coave Therapeutics unveils lead gene therapy program for retinal vascular diseases, powered by first-in-class vector for suprachoroidal delivery. CoTx-101 represents a potential b ...
Dyno Therapeutics unveils best-in-class Dyno-bn8 AAV vector for muscle gene therapies, achieving therapeutic delivery with improved safety potential ...